Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 6/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7918979 | 0.90 | ALDH1A1 (0.55) | ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7918554 | 0.89 | ALDH1A1 (0.76) | ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7920840 | 0.89 | ALDH1A1 (0.66) | ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7920720 | 0.87 | ALDH1A1 (0.59) | ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7920759 | 0.87 | ALDH1A1 (0.79) | ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7918890 | 0.86 | ALDH1A1 (0.62) | ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7924026 | 0.82 | ALDH1A1 (0.60) | ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7924091 | 0.81 | ALDH1A1 (0.58) | ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7920700 | 0.80 | ALDH1A1 (0.52) | ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7911871 | 0.80 | ALDH1A1 (0.57) | ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321252-A1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | Public University Corporation Yokohama City University (JP) | 2018-05-16 | — | — | EP | claimed |
| EP-3321252-B1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | PUBLIC UNIV CORP YOKOHAMA CITY UNIV (JP) | 2020-10-21 | — | — | EP | disclosed |
| EP-3569229-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS | Public University Corporation Yokohama City University (JP) | 2019-11-20 | — | — | EP | disclosed |
| US-10335503-B2 | Compound that specifically binds to AMPA receptor | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20180200391-A1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2018-07-19 | — | — | US | disclosed |
| EP-3321252-A1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | Public University Corporation Yokohama City University (JP) | 2018-05-16 | — | — | EP | disclosed |
| EP-0811375-B1 | GLUTAMIC ACID RECEPTOR AGONIST | NIPPON SUISAN KAISHA LTD (JP) | 2001-01-03 | — | — | EP | disclosed |
| US-5955505-A | TREATING NERVE DEGENERATIVE DISORDERS | NIPPON SUISAN KAISHA, LTD. (JP) | 1999-09-21 | — | — | US | disclosed |
| EP-0811375-A1 | GLUTAMIC ACID RECEPTOR AGONIST | NIPPON SUISAN KAISHA, LTD. (JP) | 1997-12-10 | — | — | EP | disclosed |
| EP-0469901-B1 | Sulfonamide derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5189211-A | Thromboxane A2 antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1993-02-23 | — | — | US | disclosed |
| EP-0469901-A1 | Sulfonamide derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180200391-A1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | GRM3, GRM1, GRIN3A | ALDH1A1 2376/4885HSD17B10 2229/4885CYP1A2 3393/4885 |
| US-10335503-B2 | Compound that specifically binds to AMPA receptor | GRM3, GRIN3A, GRM1 | ALDH1A1 2218/4885HSD17B10 2432/4885CYP1A2 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.